Cargando…
Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease: focus on heart failure and renal outcomes
The kidney has a prominent role in maintaining glucose homeostasis by using glucose as a metabolic substrate. This occurs by generating glucose through gluconeogenesis, and by reuptaking filtered glucose through the sodium–glucose cotransporters SGLT1 and SGLT2 located in the proximal tubule. In rec...
Autores principales: | Gronda, Edoardo G., Vanoli, Emilio, Iacoviello, Massimo, Urbinati, Stefano, Caldarola, Pasquale, Colivicchi, Furio, Gabrielli, Domenico |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801273/ https://www.ncbi.nlm.nih.gov/pubmed/35098383 http://dx.doi.org/10.1007/s10741-021-10211-9 |
Ejemplares similares
-
ANMCO POSITION PAPER: on administration of type 2 sodium-glucose co-transporter inhibitors to prevent heart failure in diabetic patients and to treat heart failure patients with and without diabetes
por: Gronda, Edoardo, et al.
Publicado: (2021) -
The Benefit of Sodium-Glucose Co-Transporter Inhibition in Heart Failure: The Role of the Kidney
por: Gronda, Edoardo, et al.
Publicado: (2022) -
ANMCO POSITION PAPER: Use of sacubitril/valsartan in hospitalized patients with acute heart failure
por: Di Tano, Giuseppe, et al.
Publicado: (2021) -
The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction
por: Gronda, Edoardo, et al.
Publicado: (2020) -
Renal Oxygen Demand and Nephron Function: Is Glucose a Friend or Foe?
por: Gronda, Edoardo, et al.
Publicado: (2023)